Medical - Devices
Compare Stocks
4 / 10Stock Comparison
SNWV vs MLSS vs NVCR vs MMSI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
SNWV vs MLSS vs NVCR vs MMSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $134M | $36M | $2.04B | $3.65B |
| Revenue (TTM) | $41M | $9M | $674M | $1.54B |
| Net Income (TTM) | $-7M | $-7M | $-173M | $139M |
| Gross Margin | 77.7% | 72.8% | 75.2% | 48.7% |
| Operating Margin | 16.6% | -77.0% | -27.2% | 12.2% |
| Forward P/E | 42.1x | — | — | 15.1x |
| Total Debt | $25M | $349K | $290M | $898M |
| Cash & Equiv. | $10M | $3M | $103M | $449M |
SNWV vs MLSS vs NVCR vs MMSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SANUWAVE Health, In… (SNWV) | 100 | 15.1 | -84.9% |
| Milestone Scientifi… (MLSS) | 100 | 24.8 | -75.2% |
| NovoCure Limited (NVCR) | 100 | 26.5 | -73.5% |
| Merit Medical Syste… (MMSI) | 100 | 136.2 | +36.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNWV vs MLSS vs NVCR vs MMSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SNWV is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 60.0%, EPS growth 42.3%, 3Y rev CAGR 35.9%
- 60.0% revenue growth vs MLSS's -12.2%
MLSS lags the leaders in this set but could rank higher in a more targeted comparison.
NVCR is the clearest fit if your priority is momentum.
- +2.6% vs MLSS's -52.9%
MMSI carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.66
- 209.3% 10Y total return vs SNWV's -25.9%
- Lower volatility, beta 0.66, Low D/E 56.7%, current ratio 4.34x
- Beta 0.66, current ratio 4.34x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 60.0% revenue growth vs MLSS's -12.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.0% margin vs MLSS's -76.8% | |
| Stability / Safety | Beta 0.66 vs NVCR's 2.15, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +2.6% vs MLSS's -52.9% | |
| Efficiency (ROA) | 5.2% ROA vs MLSS's -86.6%, ROIC 7.2% vs -121.3% |
SNWV vs MLSS vs NVCR vs MMSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SNWV vs MLSS vs NVCR vs MMSI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MMSI leads in 2 of 6 categories
SNWV leads 1 • MLSS leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SNWV leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MMSI is the larger business by revenue, generating $1.5B annually — 169.8x MLSS's $9M. MMSI is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to MLSS's -76.8%. On growth, MLSS holds the edge at +25.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $41M | $9M | $674M | $1.5B |
| EBITDAEarnings before interest/tax | $8M | -$7M | -$165M | $290M |
| Net IncomeAfter-tax profit | -$7M | -$7M | -$173M | $139M |
| Free Cash FlowCash after capex | -$784,000 | -$5M | -$48M | $274M |
| Gross MarginGross profit ÷ Revenue | +77.7% | +72.8% | +75.2% | +48.7% |
| Operating MarginEBIT ÷ Revenue | +16.6% | -77.0% | -27.2% | +12.2% |
| Net MarginNet income ÷ Revenue | -17.1% | -76.8% | -25.7% | +9.0% |
| FCF MarginFCF ÷ Revenue | -1.9% | -57.9% | -7.1% | +17.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.3% | +25.3% | +12.3% | +7.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +117.4% | — | -100.0% | +38.8% |
Valuation Metrics
MMSI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, MMSI's 12.9x EV/EBITDA is more attractive than SNWV's 22.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $134M | $36M | $2.0B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $149M | $33M | $2.2B | $4.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.21x | -7.73x | -14.66x | 28.77x |
| Forward P/EPrice ÷ next-FY EPS est. | 42.08x | — | — | 15.05x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 22.67x | — | — | 12.87x |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 4.16x | 3.11x | 2.41x |
| Price / BookPrice ÷ Book value/share | — | 6.25x | 5.86x | 2.34x |
| Price / FCFMarket cap ÷ FCF | 67.95x | — | — | 16.95x |
Profitability & Efficiency
MMSI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MMSI delivers a 8.9% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-2 for MLSS. MLSS carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), SNWV scores 7/9 vs MLSS's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -2.1% | -50.8% | +8.9% |
| ROA (TTM)Return on assets | -21.7% | -86.6% | -16.5% | +5.2% |
| ROICReturn on invested capital | +159.8% | -121.3% | -16.4% | +7.2% |
| ROCEReturn on capital employed | — | -94.2% | -28.9% | +7.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.06x | 0.85x | 0.57x |
| Net DebtTotal debt minus cash | $15M | -$3M | $187M | $450M |
| Cash & Equiv.Liquid assets | $10M | $3M | $103M | $449M |
| Total DebtShort + long-term debt | $25M | $349,054 | $290M | $898M |
| Interest CoverageEBIT ÷ Interest expense | 0.13x | — | -96.80x | 10.74x |
Total Returns (Dividends Reinvested)
Evenly matched — SNWV and MMSI each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MMSI five years ago would be worth $9,727 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, NVCR leads with a +2.6% total return vs MLSS's -52.9%. The 3-year compound annual growth rate (CAGR) favors SNWV at 25.9% vs NVCR's -36.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -46.1% | +57.6% | +36.4% | -29.1% |
| 1-Year ReturnPast 12 months | -50.6% | -52.9% | +2.6% | -36.2% |
| 3-Year ReturnCumulative with dividends | +99.6% | -39.1% | -74.2% | -27.8% |
| 5-Year ReturnCumulative with dividends | -73.9% | -80.6% | -90.2% | -2.7% |
| 10-Year ReturnCumulative with dividends | -25.9% | -80.4% | +38.5% | +209.3% |
| CAGR (3Y)Annualised 3-year return | +25.9% | -15.2% | -36.4% | -10.3% |
Risk & Volatility
Evenly matched — NVCR and MMSI each lead in 1 of 2 comparable metrics.
Risk & Volatility
MMSI is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 89.2% from its 52-week high vs SNWV's 33.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 0.85x | 2.15x | 0.66x |
| 52-Week HighHighest price in past year | $46.59 | $1.05 | $20.06 | $100.19 |
| 52-Week LowLowest price in past year | $15.36 | $0.22 | $9.82 | $59.74 |
| % of 52W HighCurrent price vs 52-week peak | +33.4% | +43.5% | +89.2% | +61.2% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 79.7 | 70.9 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 85K | 2.3M | 1.4M | 758K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SNWV as "Buy", NVCR as "Buy", MMSI as "Buy". Consensus price targets imply 246.8% upside for SNWV (target: $54) vs 55.1% for MMSI (target: $95).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $54.00 | — | $33.50 | $95.00 |
| # AnalystsCovering analysts | 2 | — | 15 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
MMSI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). SNWV leads in 1 (Income & Cash Flow). 2 tied.
SNWV vs MLSS vs NVCR vs MMSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNWV or MLSS or NVCR or MMSI a better buy right now?
For growth investors, SANUWAVE Health, Inc.
(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Merit Medical Systems, Inc. (MMSI) offers the better valuation at 28. 8x trailing P/E (15. 1x forward), making it the more compelling value choice. Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNWV or MLSS or NVCR or MMSI?
On forward P/E, Merit Medical Systems, Inc.
is actually cheaper at 15. 1x.
03Which is the better long-term investment — SNWV or MLSS or NVCR or MMSI?
Over the past 5 years, Merit Medical Systems, Inc.
(MMSI) delivered a total return of -2. 7%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MMSI returned +209. 3% versus MLSS's -80. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNWV or MLSS or NVCR or MMSI?
By beta (market sensitivity over 5 years), Merit Medical Systems, Inc.
(MMSI) is the lower-risk stock at 0. 66β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 224% more volatile than MMSI relative to the S&P 500. On balance sheet safety, Milestone Scientific Inc. (MLSS) carries a lower debt/equity ratio of 6% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — SNWV or MLSS or NVCR or MMSI?
By revenue growth (latest reported year), SANUWAVE Health, Inc.
(SNWV) is pulling ahead at 60. 0% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: SANUWAVE Health, Inc. grew EPS 42. 3% year-over-year, compared to 4. 9% for Merit Medical Systems, Inc.. Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNWV or MLSS or NVCR or MMSI?
Merit Medical Systems, Inc.
(MMSI) is the more profitable company, earning 8. 5% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNWV leads at 16. 6% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNWV or MLSS or NVCR or MMSI more undervalued right now?
On forward earnings alone, Merit Medical Systems, Inc.
(MMSI) trades at 15. 1x forward P/E versus 42. 1x for SANUWAVE Health, Inc. — 27. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNWV: 246. 8% to $54. 00.
08Which pays a better dividend — SNWV or MLSS or NVCR or MMSI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SNWV or MLSS or NVCR or MMSI better for a retirement portfolio?
For long-horizon retirement investors, Merit Medical Systems, Inc.
(MMSI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), +209. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MMSI: +209. 3%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNWV and MLSS and NVCR and MMSI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SNWV is a small-cap high-growth stock; MLSS is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.